Literature DB >> 25119967

FGFR3-related condition: a skeletal dysplasia with similarities to thanatophoric dysplasia and SADDAN due to Lys650Met.

Shannon G Farmakis1, Marwan Shinawi, Michelle Miller-Thomas, Alireza Radmanesh, Thomas E Herman.   

Abstract

Mutations in the fibroblast growth factor receptor 3 (FGFR3) gene account for six related skeletal dysplasia conditions: achondroplasia, hypochondroplasia, thanatophoric dysplasia types 1 and 2, SADDAN (severe achondroplasia with developmental delay and acanthosis nigricans), and platyspondylic lethal skeletal dysplasia, San Diego type. This group of disorders has very characteristic clinical and radiologic features, which distinguish them from other skeletal dysplasias. They display a spectrum of severity in the skeletal findings, ranging from relatively mild hypochondroplasia to lethal thanatophoric dysplasia. We report a patient who has the missense FGFR3 mutation, Lys650Met, previously reported in association only with SADDAN, who exhibits some findings similar to both thanatophoric dysplasia (types 1 and 2) in addition to those findings characteristic of SADDAN.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25119967     DOI: 10.1007/s00256-014-1983-6

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  8 in total

Review 1.  Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.

Authors:  Silvie Foldynova-Trantirkova; William R Wilcox; Pavel Krejci
Journal:  Hum Mutat       Date:  2011-11-16       Impact factor: 4.878

Review 2.  Brain and bone abnormalities of thanatophoric dwarfism.

Authors:  Elka Miller; Susan Blaser; Patrick Shannon; Elysa Widjaja
Journal:  AJR Am J Roentgenol       Date:  2009-01       Impact factor: 3.959

3.  Long-term survival in typical thanatophoric dysplasia type 1.

Authors:  K M Baker; D S Olson; C O Harding; R M Pauli
Journal:  Am J Med Genet       Date:  1997-06-27

4.  Novel FGFR3 mutations creating cysteine residues in the extracellular domain of the receptor cause achondroplasia or severe forms of hypochondroplasia.

Authors:  Solange Heuertz; Martine Le Merrer; Bernhard Zabel; Michael Wright; Laurence Legeai-Mallet; Valérie Cormier-Daire; Linda Gibbs; Jacky Bonaventure
Journal:  Eur J Hum Genet       Date:  2006-08-16       Impact factor: 4.246

5.  Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype.

Authors:  G A Bellus; E B Spector; P W Speiser; C A Weaver; A T Garber; C R Bryke; J Israel; S S Rosengren; M K Webster; D J Donoghue; C A Francomano
Journal:  Am J Hum Genet       Date:  2000-10-27       Impact factor: 11.025

6.  A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene.

Authors:  P L Tavormina; G A Bellus; M K Webster; M J Bamshad; A E Fraley; I McIntosh; J Szabo; W Jiang; E W Jabs; W R Wilcox; J J Wasmuth; D J Donoghue; L M Thompson; C A Francomano
Journal:  Am J Hum Genet       Date:  1999-03       Impact factor: 11.025

7.  Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3.

Authors:  G A Bellus; M J Bamshad; K A Przylepa; J Dorst; R R Lee; O Hurko; E W Jabs; C J Curry; W R Wilcox; R S Lachman; D L Rimoin; C A Francomano
Journal:  Am J Med Genet       Date:  1999-07-02

8.  Prenatal and postnatal presentation of severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN) due to the FGFR3 Lys650Met mutation.

Authors:  Andreas Zankl; George Elakis; Rachel D Susman; Garry Inglis; Glenn Gardener; Michael F Buckley; Tony Roscioli
Journal:  Am J Med Genet A       Date:  2008-01-15       Impact factor: 2.802

  8 in total
  2 in total

Review 1.  Achondroplasia: Development, pathogenesis, and therapy.

Authors:  David M Ornitz; Laurence Legeai-Mallet
Journal:  Dev Dyn       Date:  2017-03-02       Impact factor: 3.780

Review 2.  Achondroplasia: a comprehensive clinical review.

Authors:  Richard M Pauli
Journal:  Orphanet J Rare Dis       Date:  2019-01-03       Impact factor: 4.123

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.